摘要
目的:初步探讨应用微粒-经肝动脉化疗栓塞(m-TACE)治疗肝细胞癌(HCC)术后外周血中CD4^(+)程序性死亡受体1(PD-1)、CD8^(+)PD-1的变化及意义。方法:选取2021—2022年北京清华长庚医院肝胆胰中心临床资料完整的20例有m-TACE治疗指征的中晚期HCC患者(HCC组),选择非酒精性肝硬化患者及健康志愿者各12例作为肝硬化组和健康组。应用流式细胞术检测健康组、肝硬化组和HCC患者m-TACE术前与术后1~2周外周血中CD4^(+)PD-1、CD8^(+)PD-1表达情况。结果:HCC组外周血CD4^(+)PD-1、CD8^(+)PD-1表达均明显高于肝硬化组及健康组。HCC患者经m-TACE治疗后1~2周外周血CD4^(+)PD-1表达由治疗前(38.65±8.56)%下降至(31.65±5.81)%(P<0.05),同样CD8^(+)PD-1表达也较治疗前下降[(41.17±12.12)%∶(29.29±10.48)%,P<0.05]。m-TACE治疗后疗效好的患者术后外周血PD-1表达较低。结论:m-TACE治疗HCC可能降低外周血CD4^(+)/CD8^(+)PD-1的表达。
Objective:To explore the changes and significance of CD4^(+)programmed death receptor 1(PD-1)and CD8^(+)PD-1 in peripheral blood after hepatocellular carcinoma(HCC)patient streated with microparticles transcatheter arterial chemoembolization(m-TACE).Method:From 2021 to 2022,20 patients with intermediate and advanced HCC with indications for m-TACE treatment were selected from the Hepatobiliary and Pancreatic Center of Beijing Tsinghua Chang Gung Hospital(HCC group),and 12 patients with non-alcoholic cirrhosis and 12 healthy volunteers were selected as cirrhosis group and healthy group.Flow cytometry was used to detect the expression of CD4^(+)PD-1 and CD8^(+)PD-1 in peripheral blood of healthy,cirrhotic,and liver cancer patients before and 1-2 weeks after m-TACE.Result:The expression of CD4^(+)/CD8^(+)PD-1 in peripheral blood of the HCC group was significantly higher than that of the liver cirrhosis group and the healthy group.After 1-2 weeks of m-TACE,the expression of CD4^(+)/CD8^(+)PD-1 of HCC patients decreased compared to before treatment(P<0.05).Patients with good therapeutic effects after m-TACE have lower expression of CD4^(+)/CD8^(+)PD-1 in peripheral blood(P<0.05).Conclusion:m-TACE treatment for HCC can reduce the expression of CD4^(+)/CD8^(+)PD-1 in peripheral blood.
作者
任志忠
岳元勋
汪桠琴
王雅静
张跃伟
Ren Zhizhong;Yue Yuanxun;Wang Yaqin;Wang Yajing;Zhang Yuewei(Department of Hepatobiliary Interventional,Hepatobiliary Pancreatic Center,Beijing Tsinghua Changgeng Hospital,Beijing 102218,China;Department of Pain,Beijing Luhe Hospital Affiliated with Capital Medical University,Beijing 101149,China)
出处
《肝癌电子杂志》
2023年第3期48-51,共4页
Electronic Journal of Liver Tumor
基金
清华大学精准医学科研计划(10001020103)
首都卫生发展科研专项(首发2020-2-2242)。
关键词
肝细胞癌
经导管动脉化疗栓塞
程序性死亡受体1
免疫治疗
Hepatocellular carcinoma
Transcatheter arterial chemoembolization
Programmed death receptor 1
Immunotherapy
